ClinicalTrials.gg
Not yet recruitingNCT07849803AURORAUpdated Oct 6, 2026

Effect of Acoltremon Ophthalmic Solution 0.003% on Tear Production and Symptoms in Patients With Tear Deficiency and Concurrent Neuropathic Corneal Pain

A Phase 4 interventional study of acoltremon ophthalmic solution 0.003% in Ocular Pain and Dry Eye, sponsored by University of South Florida. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by University of South Florida · Phase 4, Interventional, and Treatment

How we know

Updated Oct 6, 2026Primary outcomes revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Eye Pain with a site in United States — 3 open to participants now, 4 under way, 1 of them phase 3. Eye Pain · United States.

Planned enrollment
13th of 16
28 · median 70
Started
2026
with 1 other
Phase 4
4 of 17
1 open now
Registered
17th of 17
by date
Lead sponsor
1 of 17
University of South Florida

Among the 17 studies in Eye Pain with a site in United States, this one is the 13th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 4, and was the 17th registered.

Eye Pain

31 studies on the registry are indexed under Eye Pain; 7 are open to participants now.

Browse Eye Pain studies →

Open to participants now

3 of the 17 studies in Eye Pain with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Eye Pain studies recruiting now, 1 sets no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Eye Pain with a site in United States, or all of them as a file.
02

Study summary

This study is designed to provide clinical data on how acoltremon ophthalmic solution 0.003% affects tear production and ocular symptoms in participants with tear deficiency and concurrent neuropathic corneal pain. Acoltremon is formulated to help increase natural tear production by activating TRPM8 (Transient Receptor Potential Melastatin 8) receptors on cold-sensitive corneal nerves. It is thought that this study treatment may help participants by increasing tear production while potentially reducing neuropathic ocular symptoms, including pain and discomfort.

Participants will be followed for 8 weeks, evaluating the mean change in unanesthetized Schirmer test score between 3 minutes post-drop at Week 8 compared to pre-drop at baseline (Day 1), change in neuropathic symptom intensity as measured by a 0-10 VAS (Visual Analog Scale) from baseline to Week 8, and change in quality of life as assessed by the Ocular Pain Assessment Survey (OPAS) from baseline to Week 8. The study will also evaluate changes in corneal nerve structure, nerve function, corneal sensitivity, ocular surface symptoms, and treatment satisfaction.

Read the detailed description

AURORA is a prospective, open-label, single-center, single-arm investigator-initiated study evaluating TRYPTYR (acoltremon ophthalmic solution 0.003%) in 28 adults with neuropathic corneal pain and concurrent tear deficiency. Eligible participants must have neuropathic ocular symptoms for at least 3 months, a driving symptom score of at least 4 on a 0-10 VAS (Visual Analog Scale), reduced corneal nerve density and microneuromas on IVCM (In Vivo Confocal Microscopy), at least 50% symptom improvement following topical proparacaine, and an unanesthetized Schirmer score of at least 2 mm but less than 10 mm.

Participants will administer acoltremon 0.003% in both eyes twice daily for 8 weeks. One qualifying eye per participant will be designated as the study eye for analysis. There is no placebo or comparator group.

The primary endpoint is the mean change in unanesthetized Schirmer score from pre-drop baseline to 3 minutes post-drop at Week 8. Secondary endpoints include acute change in Schirmer score on Day 1, change in neuropathic ocular symptom intensity on the VAS (Visual Analog Scale), and change in quality of life measured by OPAS (Ocular Pain Assessment Survey). Exploratory outcomes include changes in corneal nerve structure and function, corneal sensitivity, OSDI (Ocular Surface Disease Index) scores, drop comfort, and treatment satisfaction.

Safety monitoring will focus on corneal staining, visual acuity, discomfort following drop administration, and adverse events, with a safety assessment conducted after the first five participants.

03

Conditions studied

  • Ocular Pain
  • Dry Eye

Keywords

  • Dry Eye
  • Eye pain
  • tear deficiency
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged ≥ 18 years
  2. Baseline unanesthetized Schirmer test ≥2 and \< 10 mm
  3. Symptoms of neuropathic corneal pain (such as burning, stinging, light sensitivity, discomfort, or pain) for at least 3 months with driving symptom rated at level 4 or higher on VAS.
  4. Positive IVCM findings evaluated by an experienced ophthalmologist (Pedram Hamrah, MD): for decreased nerve density AND evidence of microneuromas.
  5. Females of must have a negative pregnancy test.
  6. Change of 50% or more improvement in VAS score after topical 0.5% proparacaine hydrochloride (Alcaine, Alcon, Fort Worth, TX).

Exclusion criteria

Exclusion Criteria:

  1. Evidence of any active ocular infection or any intraocular inflammation.
  2. Evidence of any persistent epithelial defect/ulcer or any corneal scar/corneal edema.
  3. Presence of any other ocular conditions that require topical medications during the treatment phase.
  4. History of severe systemic allergies or severe ocular allergies.
  5. Inability to suspend topical medications and varenicline 8 days prior to the starting date, except for artificial and serum tears for which subjects must be stable on current regimen for ≥3 months with no changes during the trial.
  6. History of any ocular surgery within three months before study Visit 1.
  7. Ocular surgery expected during the duration of the study.
  8. Use of refractive/therapeutic contact lenses during the study period.
  9. Female subjects who are pregnant/have a positive pregnancy test result or are breastfeeding or intend to become pregnant during the study treatment period.
  10. Drug addiction/alcohol abuse within the last year.
  11. Participation in another clinical trial concurrently.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Acoltremon Group

    Patients will administer one drop of Acoltremon Ophthalmic Solution 0.003% twice a day for 8 weeks.

    Drug: acoltremon ophthalmic solution 0.003%

Interventions

  • DrugAcoltremonStudies of AcoltremonAcoltremon pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    acoltremon ophthalmic solution 0.003%, one drop, twice a day, into the study eye, for 8 weeks.

06

What researchers measure

Primary outcomes

  1. Change in Unanesthetized Schirmer Test Score at Week 8

    Mean change from the pre-dose measurement at baseline (Day 1) to the measurement taken 3 minutes after dosing at Week 8. Range: 0-35 mm Interpretation: Higher scores indicate greater tear production and a better outcome.

    Time frame: Time frame: Baseline to Week 8

Secondary outcomes

  1. Acute Change in Unanesthetized Schirmer Test Score on Day 1

    Mean change from the pre-dose measurement to the measurement taken 3 minutes after the first dose. Range: 0-35 mm Interpretation: Higher scores indicate greater tear production and a better outcome.

    Time frame: Pre-dose to 3 minutes post-dose on Day 1

  2. Change in Neuropathic Ocular Symptom Intensity

    Change in pain, discomfort, or another identified neuropathic symptom measured using a 0-10 visual analog scale (VAS). Range: 0-10 Interpretation: Higher scores indicate greater pain or symptom severity and a worse outcome.

    Time frame: Baseline to Week 8

  3. Change in Ocular Pain-Related Quality of Life

    Change in quality of life measured using the Ocular Pain Assessment Survey (OPAS). Range: 0-10 Interpretation: Higher scores indicate greater ocular pain and symptom severity and a worse outcome.

    Time frame: Baseline to Week 8

07

Study locations

1 site
08

References and documents

Publications

  • Rolke R, Baron R, Maier C, Tolle TR, Treede -DR, Beyer A, Binder A, Birbaumer N, Birklein F, Botefur IC, Braune S, Flor H, Huge V, Klug R, Landwehrmeyer GB, Magerl W, Maihofner C, Rolko C, Schaub C, Scherens A, Sprenger T, Valet M, Wasserka B. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain. 2006 Aug;123(3):231-243. doi: 10.1016/j.pain.2006.01.041. Epub 2006 May 11. PubMed 16697110 ↗
  • Villani E, Baudouin C, Efron N, Hamrah P, Kojima T, Patel SV, Pflugfelder SC, Zhivov A, Dogru M. In vivo confocal microscopy of the ocular surface: from bench to bedside. Curr Eye Res. 2014 Mar;39(3):213-31. doi: 10.3109/02713683.2013.842592. Epub 2013 Nov 11. PubMed 24215436 ↗
  • Qazi Y, Hurwitz S, Khan S, Jurkunas UV, Dana R, Hamrah P. Validity and Reliability of a Novel Ocular Pain Assessment Survey (OPAS) in Quantifying and Monitoring Corneal and Ocular Surface Pain. Ophthalmology. 2016 Jul;123(7):1458-68. doi: 10.1016/j.ophtha.2016.03.006. Epub 2016 Apr 16. PubMed 27089999 ↗
  • Dieckmann G, Goyal S, Hamrah P. Neuropathic Corneal Pain: Approaches for Management. Ophthalmology. 2017 Nov;124(11S):S34-S47. doi: 10.1016/j.ophtha.2017.08.004. PubMed 29055360 ↗
  • Galor A, Levitt RC, Felix ER, Martin ER, Sarantopoulos CD. Neuropathic ocular pain: an important yet underevaluated feature of dry eye. Eye (Lond). 2015 Mar;29(3):301-12. doi: 10.1038/eye.2014.263. Epub 2014 Nov 7. PubMed 25376119 ↗
  • Belmonte C, Nichols JJ, Cox SM, Brock JA, Begley CG, Bereiter DA, Dartt DA, Galor A, Hamrah P, Ivanusic JJ, Jacobs DS, McNamara NA, Rosenblatt MI, Stapleton F, Wolffsohn JS. TFOS DEWS II pain and sensation report. Ocul Surf. 2017 Jul;15(3):404-437. doi: 10.1016/j.jtos.2017.05.002. Epub 2017 Jul 20. PubMed 28736339 ↗
  • Marfurt C, Anokwute MC, Fetcko K, Mahony-Perez E, Farooq H, Ross E, Baumanis MM, Weinberg RL, McCarron ME, Mankowski JL. Comparative Anatomy of the Mammalian Corneal Subbasal Nerve Plexus. Invest Ophthalmol Vis Sci. 2019 Dec 2;60(15):4972-4984. doi: 10.1167/iovs.19-28519. PubMed 31790560 ↗
  • Cruzat A, Qazi Y, Hamrah P. In Vivo Confocal Microscopy of Corneal Nerves in Health and Disease. Ocul Surf. 2017 Jan;15(1):15-47. doi: 10.1016/j.jtos.2016.09.004. Epub 2016 Oct 19. PubMed 27771327 ↗
  • Marfurt CF, Cox J, Deek S, Dvorscak L. Anatomy of the human corneal innervation. Exp Eye Res. 2010 Apr;90(4):478-92. doi: 10.1016/j.exer.2009.12.010. Epub 2009 Dec 29. PubMed 20036654 ↗

Individual participant data

Plan to share: No — The University of South Florida Eye Institute is not a pharmacy distribution company, the information being collected is for medical science to improve patient care options.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for May 2027, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartEst.
Oct 2026
Primary completionEst.
May 2027
CompletionEst.
Jun 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionChange in Unanesthetized Schirmer Test Score at Week 8: how it is measured was reworded
Oct 6, 2026
Secondary outcomes
3 description edited
What changed in the outcomes
  • DescriptionAcute Change in Unanesthetized Schirmer Test Score on Day 1: how it is measured was reworded
  • DescriptionChange in Neuropathic Ocular Symptom Intensity: how it is measured was reworded
  • DescriptionChange in Ocular Pain-Related Quality of Life: how it is measured was reworded
Oct 6, 2026
Registered
First appeared on the registry
Sep 30, 2026
Show all 2 updates
  1. Oct 6, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionChange in Unanesthetized Schirmer Test Score at Week 8: how it is measured was reworded
    Secondary outcomes 3 description edited
    What changed in the outcomes
    • DescriptionAcute Change in Unanesthetized Schirmer Test Score on Day 1: how it is measured was reworded
    • DescriptionChange in Neuropathic Ocular Symptom Intensity: how it is measured was reworded
    • DescriptionChange in Ocular Pain-Related Quality of Life: how it is measured was reworded
    + 3 other changes: verification date, description and data sharing statement
  2. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07849803
Collaborators
Alcon Research
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Oct 2026 (estimated)
Primary completion
May 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Mya L. Reese
Contact
MCOM-Eyeresearch@usf.edu
18139742020
Susan Sherouse
Contact
MCOM-Eyeresearch@usf.edu
8139742020
Pedram Hamrah, MD
principal investigator · University of South Florida/Ophthalmology

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acoltremon

Start the discussion